Market Research Report
Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028
|Published by||DelveInsight Business Research LLP||Product code||905937|
|Published||Content info||87 Pages
Delivery time: 1-2 business days
|Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028|
|Published: August 1, 2019||Content info: 87 Pages||
DelveInsight's 'Generalized Myasthenia Gravis (gMG)-Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Generalized Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2028
The Generalized Myasthenia Gravis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Generalized Myasthenia Gravis are studied through all possible division to give a better understanding of the disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The epidemiology is segmented by total diagnosed prevalent cases and auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2028.
According to DelveInsight, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017.